RT Journal Article
SR Electronic
T1 Early estimates of COVID-19 infections in small, medium and large population clusters
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.07.20053421
DO 10.1101/2020.04.07.20053421
A1 Siraj, DS
A1 Siraj, AS
A1 Mapes, A
YR 2020
UL http://medrxiv.org/content/early/2020/04/11/2020.04.07.20053421.abstract
AB Since its emergence in December 2019, COVID-19 has rapidly developed into a pandemic with many countries declaring emergency conditions to contain its spread. The impact of the disease, while has been relatively low in the Sub Saharan Africa (SSA) so far, is expected to be devastating given the less developed and fragmented health care system in the continent. In addition, most emergency measures such as border closings, cancellations of inbound flights, social distancing, and promotion of hand hygiene may not be as effective due to the clustered way people live in large as well as smaller population centers. As SSA waits for the start of large epidemics as seem in other regions, there exist acute need for estimates of the potential impacts of the disease once it gets strong hold in the region. To address this need, we developed a mathematical model with key parameters obtained from recent studies, to estimate the number of infections with in the first 90 days of the transmission under 54 scenarios of population sizes, initial number of cases, and coverage of contact tracing and isolation. Our results show that if implemented early, 80% contact tracing may “flattens the curve” of local epidemics, brings the pandemic to a manageable level for all population sizes we assessed. In countries with limited workforce, hospital resources and ICU care, a robust contact tracing program could yield in outcomes that prevent several millions of infections and thousands of deaths across the continent.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis paper does not used data apart from model parameters.